Page 202 - ebook HCC

PROGRAMME
GENEVA, SWITZERLANDA, SWITZERLAND
EASL HCC SUMMITHCC SUMMIT
200 PROGRAMME AND ABSTRACTSAND ABSTRACTS GENEV EASL 201
200
201
FEBRUARY 13 - 16, 2014Y 13 - 16, 2014
FEBRUAR
Poster Board Number C4 Poster Board Number C5
EVALUATION OF COMBINED SORAFENIB FOR ADVANCED HEPATOCELLULAR
RADIOFREQUENCY ABLATION FOLLOWED CARCINOMA IN PATIENTS WITH ALCOHOLIC
BY CHEMOEMBOLIZATION VERSUS CIRRHOSIS AND COMORBIDITIES. EFFICACY
CHEMOEMBOLIZATION IN MANAGEMENT OF AND TOLERABILITY IN REAL-LIFE SETTING
HEPATOCELLULAR CARCINOMA PATIENTS

Petros Giovanis , Valter Vincenzi , Carla Manuppelli , Marilisa Marcante , Dagmar
2
1
2
1
Ahmed K. El Dorry , Nevien F. Elfouly , Eman M. F. Barakat , Amal T. AbdElMoez , Dannhauser , Laura Ciasullo , Viviana Lovat , Mauro Giusto , Massimo Boaretto 2
3
1
2
3
1
2
2
2
Mervet A. F. Mawad , Mohammed K. Shaker 2 1 Medical Oncology, Internal Medicine and Hepatoloy, Pharmacy, Azienda Ulss 1,
3
3
2
1 Department of Radiology Medicine, Faculty of Medicine, Ain Shams University, Egypt, Belluno, Italy, Belluno, Italy
2 Department of Tropical Medicine, Faculty of Medicine, Ain Shams University, Egypt,
3 Atomic Energy Authority, Egypt Corresponding author’s e-mail: pgiova@racine.ra.it
Corresponding author’s e-mail: d_amal_tohamy@yahoo.com Introduction: Sorafenib has shown survival benefit in patients with hepatocellular
carcinoma (HCC). HCC from alcoholic cirrhosis is a severe liver disease.
Introduction: Hepatocellular carcinoma (HCC), is the third most common cause of
cancer-related death. If left untreated, liver cancer has a poor prognosis. Aims: Scanty data concerning the efficacy of sorafenib in these patients are available.
Methodology: Since February 2009 we screened 67 Child-Pugh liver function class A
Aims: to asses the value of combined radiofrequency ablation followed by consecutive pts bearing the above characteristics. Fifty-one pts (76,1%), 49 males and
chemoembolization (RFA-TACE) versus trans-arterial chemoembolization (TACE) alone 2 females, median age of 71.5 years (range 53-80), received 400 mg sorafenib b.i.d.
in the management of hepatocellular carcinoma. Predominant cause of HCC was alcohol consumption in 39 pts (76.4%), chronic HCV/HBV
infection in 11 pts (21.5%), and hemosiderosis in 1 pt (1.9%). All but 4 pts suffered from
Results: Patients and Methods: 50 HCC patients categorized into 2 groups according multiple comorbidities, 28 of them (55%) presented cardiovascular disease and diabetes.
to the modality of locoregional treatment, 25 HCC patients treated with radiofrequency Median number of concomitant medications was 5 (range 1-11). Eleven pts never received
ablation (RFA) followed by chemoembolization within 5 days and 25 HCC patients locoregional treatment, and none had received previous systemic therapy.
treated with trans-arterial chemoembolization (TACE) alone. All patients were categorized Results: Time to progression was 4.5 months (range 1-39), overall survival 8 months
CLINICAL POSTER ABSTRACTS Results: Complete response (CR) were achieved in (100%) and (84%) of HCC patients diarrhoea in 7 (13.7%), hand-foot skin reaction in 2 pts (3.9%). Five pts (9.8%) presented CLINICAL POSTER ABSTRACTS
according to BCLC Staging System of HCC pre and post-treatment.
(2-48+). Regarding tolerability, mild and severe fatigue was presented in 16 pts (36%),
after one month from combined therapy (RFA-TACE) and TACE alone respectively. But
major cardiovascular toxicity, three of them (5.8%) life-threatening cardiovascular events:
cardiac infraction, ventricular tachycardia, transient ischemic attack and atrial fibrillation,
for lesions more than 5 cm (13.3%) of patients were more liable to partial response (PR)
respectively after 18, 39 and 3 months of sorafenib. Two out of these 5 pts (3.9%)
and progressive disease (PD) after chemoembolization alone, however non of the patients
underwent combined therapy was liable for PR and/ or PD. The rate of objective response
after 7 month was (84%) and (44%) in RFA-TACE and TACE group respectively. The local
because of severe hypocalcemia after 29 months of treatment.
tumor progression rate at one year was (16.0%) and (56.0%) in RFA-TACE and TACE presented atrial fibrillation after 6 months of treatment. One pt discontinued sorafenib
group respectively. One year disease free survival rate was (56%) and (24%) in RFA- Conclusions: Treatment with sorafenib in pts affected by HCC and alcoholic cirrhosis is
TACE and TACE group respectively, and overall survival rate was (88%) in RFA-TACE effective and well tolerated with good-level compliance.
group, while (80%) in TACE alone group.

Conclusions: Combined RFA and TACE appear to be effective modality for the treatment
of HCC in a good selected patient.